November 30, 2016 - By Dolores Ford
Seeing the trade Peter Greenleaf made he is in stock market attention today. The CEO of Sucampo Pharmaceuticals Inc and an insider, made a sale of 200,000 shares worth $3,368,807 U.S. Dollars. The average price was $16.8 per share. The trade was dated November 30, 2016 and was made public in a Form 4 filed with the Security and Exchange Commission. The Form 4 is freely accessible here. The deal will most probably not remain unnoticed as it was significant one. At the moment, he possess a total of 2,513 shares or 0.01% of the company’s total market capitalization.
Out of 9 analysts covering Sucampo Pharma (NASDAQ:SCMP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. $31 is the highest target while $14 is the lowest. The $22.75 average target is 40.09% above today’s ($16.24) stock price. Sucampo Pharma has been the topic of 21 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) earned “Buy” rating by UBS on Tuesday, February 9. The firm has “Hold” rating given on Thursday, August 4 by Jefferies. TH Capital reinitiated Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Thursday, October 29 with “Buy” rating. The firm has “Mkt Perform” rating by Leerink Swann given on Thursday, September 3. As per Wednesday, August 26, the company rating was maintained by Maxim Group. The rating was maintained by Mizuho on Monday, January 18 with “Neutral”. The company was maintained on Monday, November 14 by Mizuho. Maxim Group maintained the stock with “Buy” rating in Tuesday, November 15 report. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) earned “Neutral” rating by Mizuho on Friday, November 13. The rating was initiated by Mizuho on Friday, October 9 with “Neutral”.
Insitutional Activity: The institutional sentiment is 0.98 in Q2 2016. Its the same as in 2016Q1. The ratio is the same, as 17 funds sold all Sucampo Pharmaceuticals, Inc. shares owned while 46 reduced positions. only 22 funds bought stakes while 40 increased positions. They now own 17.83 million shares or 12.41% less from 20.36 million shares in 2016Q1.
Macquarie Gru last reported 20,800 shares in the company. Lsv Asset Mgmt has invested 0.01% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Savings Bank Of Montreal Can has 25,285 shares for 0% of their US portfolio. Marshall Wace Llp owns 32,416 shares or 0% of their US portfolio. Alliancebernstein L P holds 54,962 shares or 0% of its portfolio. California State Teachers Retirement Sys has 49,118 shares for 0% of their US portfolio. Blackrock Japan Limited holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 1,698 shares. New York State Common Retirement Fund accumulated 34,970 shares or 0% of the stock. Prudential Fincl Inc, a New Jersey-based fund reported 433,653 shares. Millennium Mgmt Ltd Co has invested 0.01% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Lazard Asset Mgmt Limited Liability Com last reported 7,000 shares in the company. Princeton Alpha Lp has 0.02% invested in the company for 12,616 shares. The California-based Wells Fargo And Mn has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). State Street, a Massachusetts-based fund reported 427,527 shares. Aqr Capital Ltd Company holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 107,079 shares.
Insider Transactions: Since November 15, 2016, the stock had 0 buys, and 2 insider sales for $2.43 million net activity. Smith Andrew P had sold 1,766 shares worth $27,514. Alder Matthias had sold 150,000 shares worth $2.40M on Wednesday, November 23.
About 809,320 shares traded hands or 65.53% up from the average. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has risen 56.48% since April 27, 2016 and is uptrending. It has outperformed by 51.25% the S&P500.
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $790.97 million. The Firm focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology inflammatory disorders. It has a 54.62 P/E ratio. It operates through development and commercialization of pharmaceutical products segment.
According to Zacks Investment Research, “Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.”
Analysts await Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report earnings on March, 14. They expect $0.44 earnings per share, 0.00% or $0.00 from last year’s $0.44 per share. SCMP’s profit will be $21.43 million for 9.23 P/E if the $0.44 EPS becomes a reality. After $0.28 actual earnings per share reported by Sucampo Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 57.14% EPS growth.
More news for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) were recently published by: Bizjournals.com, which released: “Sucampo acquires exclusive option for cancer drug in deal worth up to $190 million” on January 11, 2016. Moodys.com‘s article titled: “Moody’s assigns B3 CFR to Sucampo Pharmaceuticals” and published on October 01, 2015 is yet another important article.
Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a biopharmaceutical company. The Firm focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology inflammatory disorders. The Firm operates through development and commercialization of pharmaceutical products segment. The Company’s activities are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts activities in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford